Abstract: Device, method, and computer program product for determining a material parameter of a blood coagulation cascade based on parameters of light diffused at a biofluid sample. In one example, the biofluid sample includes a blood sample. Laser light scattered by the sample is collected by the optical system in reflection and/or transmission mode. An image of the sample in so collected light is formed, and data representing fluctuations of laser speckle intensity with is processed to derive numerical descriptors associated with blood coagulation and fibrinolysis. In a specific case, such numerical descriptors are derived based on temporal dynamic of a viscoelastic characteristic of the blood sample.

Abstract: An apparatus and method for platelet multi-function analysis using measurement of electrical characteristics, and a stirring microchip are provided. The apparatus for platelet multi-function analysis includes a stirring microchip that has a sample storage chamber formed therein to hold a blood sample, and in which an inner part of the sample storage chamber is coated with reagents composed of collagen and epinephrine, or collagen and ADP. The apparatus for platelet multi-function analysis further includes a microstirrer installed inside the stirring microchip to stir the blood sample and the reagents in the stirring microchip and a stirring induction unit configured to facilitate stirring of the microstirrer. Therefore, the platelet aggregation and multi-function analysis can be performed using a trace of blood, and the platelet aggregation and multi-function analysis can also be performed using the whole blood taken from the veins through a vacuum tube containing an anticoagulant.

Abstract: The present invention discloses a system for testing microfluid which is made with a disposable disc. The high sensitivity, high sensing accuracy, and quick response microfluidic disc is demonstrated in the present invention. It is note that easy to test microfluid without traditional detecting method, and then reduce energy and simplify procedure. Furthermore, to additive the microfluidic disc is useful to enhance blood typing, and hence raising the sensitivity by the video recognition of blood agglutination.

Abstract: In order to provide a reagent kit for detecting LA which can clearly separate a lupus anticoagulant (LA)-positive specimen group from an LA-negative specimen group, it is configured that the reagent kit for detecting LA contains a first clotting time-measuring reagent and a second clotting time-measuring reagent and at least one of the first clotting time-measuring reagent and the second clotting time-measuring reagent contains alkali metal salt. The presence or absence of LA can be determined using the kit.

Abstract: A method for determining an appropriate treatment option for a patient who has been diagnosed with disseminated intravascular coagulation (DIC) but who may have thrombotic thrombocytopenic purpura (TTP), by analyzing the amount and/or enzyme activity of a von Willebrand factor (vWF)-cleaving protease (ADAMTS13) and the amount of vWF in a patient that has been diagnosed with DIC is disclosed. Using the method of the present invention, a differential diagnosis of patients with thrombotic thrombocytopenic purpura (TTP) can be made from among patients diagnosed with DIC, which could not previously be distinguished on the basis of only clinical findings or known markers. Also disclosed is a kit for determining an appropriate treatment option, the kit comprising an antibody or a fragment thereof which specifically binds to ADAMTS13.

Abstract: A diagnostic or therapeutic formulation of stable liquid coagulation factors comprises at least one coagulation factor, at least one stabilizer, and optional additives. The stabilizer is either amylopectin, galatomannan polysaccharide, agarose, agaropectin, and gelatin, or a blend of amylopectin, galatomannan polysaccharide, agarose, agaropectin, and gelatin. A preferred additive is the zwitterionic buffer 3-[N-tris(hydroxymethyl)methylamino)-2-hydroxypropane sulfonic acid (TAPSO). The stable liquid coagulation factors can be used as reagents and controls in plasma clotting assays. In addition the therapeutic formulation can be used for factor replacement therapy. The stable liquid clotting factors are made by combining the coagulation factor(s), stabilizer(s), and additive(s) in a liquid carrier and sterilizing the mixture. Coagulation factors can be concentrated by selective precipitation from plasma.

Abstract: A Disease Severity Index (DSI) is provided for assessment of chronic liver disease in a patient using non-invasive liver function test results. A DSI was derived from non-invasive liver function test results based on hepatic blood flow. The DSI is used in methods for prediction of clinical outcomes, prediction of response to antiviral treatment, and assessment of progression of chronic liver diseases. Non-invasive methods to diagnose three distinct categories of patients with Primary Sclerosing Cholangitis (PSC) are provided. The methods can be used to diagnose PSC patients as Slow Progressors, Moderate Progressors and Rapid Progressors.

Abstract: A blood coagulation system analyzing method includes acquiring information relating to the coagulability of blood based on a change generated in a complex permittivity spectrum measured in a coagulation process of the blood due to addition of a substance that activates or inactivates platelets to the blood.

Abstract: The invention relates to a method for improving the procoagulant properties of TF expressed in eukaryotic cells by contacting microvesicles derived from said eukaryotic cells with a negatively-charged phospholipid such as phosphatidylserine. The invention also relates to microvesicles obtained using said method as well as to the uses thereof as procoagulant agents, for wound healing and for promoting angiogenesis.

Abstract: Provided is the development of a convenient LA detection method in which even a sample derived from a patient who receives anticoagulant therapy of warfarin, heparin or the like, is not affected by the anticoagulant therapy, discrimination from the deficiency of blood coagulation factors is enabled, and healthy person's plasma is not used. The method for detecting lupus anticoagulant includes the following steps (A), (B) and (C): (A) a step of adding a buffer solution composition containing blood coagulation factors to each of a blood sample and a diluted sample of the blood sample before measurement or at the time of measurement of the blood coagulation time; (B) a step of measuring the blood coagulation times for the various samples of step (A); and (C) a step of comparing the blood coagulation times for the various samples obtained in step (B).

Abstract: Disclosed are antibodies that selectively bind to blood coagulation factor FVIII, and highly sensitive immunological assays comprising these antibodies. Preferred assays can detect FVIII at about 3500-fold below the normal physiological levels, and have a wide array of applications including accurate monitoring of FVIII concentration in pharmaceutical products for treatment of blood coagulation disorders, and determination of FVIII levels in plasma of human patients, including those with blood coagulation disorders such as hemophilia.

Abstract: A microorganism number-measuring apparatus includes: measurement container including measurement liquid; rotary driver; bacteria-collection signal generator; measurement signal generator; output amplifier for amplifying outputs of signal generators and; I/V amplifier; impedance measuring unit for measuring impedance of liquid; microorganism number-computing unit for computing the number of microorganisms present in liquid; solution conductivity-computing unit for computing conductivity of liquid; and warm-up section for warming up at least one of I/V amplifier and output amplifier. Warm-up section computes a warm-up signal based on the conductivity computed by conductivity-computing unit. Warm-up section computes the warm-up signal having a current the same in magnitude as that flowing through measurement electrode by using the measured solution conductivity, and applies the signal to at least one of I/V amplifier and output amplifier.

Abstract: A blood coagulation detection device includes a micro channel unit, an optical signal unit, an opto-electronic conversion circuit, an amplifier circuit, and a filter circuit. The micro channel unit has a sample detection area. The optical signal unit transmits a reference light to the micro channel unit so as to form a message light. The opto-electronic conversion circuit receives the message light and converts the message light into an electrical signal. The amplifier circuit is electrically connected to the opto-electronic conversion circuit for amplifying the electrical signal. The filter circuit is electrically connected to the amplifier circuit for filtering the amplified electrical signal.

Abstract: The present invention relates to a liquid flow device, in particular a capillary testing device provided as a chip, comprising a second pathway which intersects the first pathway at a downstream point of convergence, so that the two pathways share an outlet and when liquid in the second pathway reaches the point of convergence, liquid flow in the first pathway stops. Means for measuring the distance travelled by liquid in the first pathway are provided to determine the extent of liquid flow and to enable correlation with the amount of analyte in the liquid.

Abstract: An optical blood coagulation monitor and method. The monitor has a blood sample holder, a laser with its output light directed through the blood sample, a two-dimensional detector that is able to detect light at the laser light wavelength and that has a detector output, optics for imaging onto the detector laser light that is forward scattered by the blood, and a data analysis system, responsive to the detector output, that is adapted to analyze the detected light to provide information on time-resolved coagulation and clotting properties of the blood.

Abstract: Compositions and methods for measuring coagulation parameters using very small volumes of blood are provided. Advantageously, the methods described herein can be performed from a single drop of blood (about 20 ?L) while generally leaving enough sample to perform other measurements, optionally in a multiplexed format. The methods and devices do not require a skilled operator and can be performed at the point of service, which can be an important feature for managing blood coagulation disorders and treatments thereof.

Abstract: An assay apparatus comprising: i) an assay cartridge (52, 53) comprising at least one well (57-62) and a pipette (50) positionable in at least one said well; ii) a holder arranged to received said cartridge; iii) drive means operable to position said pipette in selected wells of said cartridge; iv) a gas pressure applicator couplable to said pipette whereby to cause liquid flow through said membrane; and v) a radiation detector operable to detect radiation from a well of said cartridge of said cartridge or from said pipette.

Abstract: An apparatus and method for platelet multi-function analysis using measurement of electrical characteristics, and a stirring microchip are provided. The apparatus for platelet multi-function analysis includes a stirring microchip that has a sample storage chamber formed therein to hold a blood sample, and in which an inner part of the sample storage chamber is coated with reagents composed of collagen and epinephrine, or collagen and ADP. The apparatus for platelet multi-function analysis further includes a microstirrer installed inside the stirring microchip to stir the blood sample and the reagents in the stirring microchip and a stirring induction unit configured to facilitate stirring of the microstirrer. Therefore, the platelet aggregation and multi-function analysis can be performed using a trace of blood, and the platelet aggregation and multi-function analysis can also be performed using the whole blood taken from the veins through a vacuum tube containing an anticoagulant.

Abstract: The invention provides new uses for specific binders to the A1 domain of the von Willebrand Factor (vWF), in particular the use in patients with stable angina undergoing elective percutaneous coronary intervention. Furthermore, dosing schedules and use of suitable assays such as RIPA and RICO in the particular disease settings are provided.

Abstract: A microfluidic-based flow assay and methods of manufacturing the same are provided. Specifically, the microfluidic flow assay includes a substrate surface comprising lipid coated particles and microfluidic channels through which a blood product can flow. The lipid coated particles comprise functional molecules that can induce or inhibit the coagulation cascade.

Abstract: A method for determining clotting time is described, of a fluid medium such as blood. This method monitors and compares the propagation of the fluid medium having a regent with a theoretical value. The clotting time is determined when monitored value deviates from the theoretical value.

Abstract: Methods and devices for analyzing fluid variables. The devices analyze fluid variables by measuring cessation of fluid flow through the medium or a change in flow rate due to an inherent property of the fluid variable, or due to a modification of the fluid variable as the fluid migrates through the medium; or by measuring relative rates of capillary flow down two or more arms of a common element of porous media in some alternatives, converging in which at least one of the arms has been modified by the addition of flow-modifying agents which affect the flow rate in response to the concentration of the analyte; or by detecting changes in the rate of the capillary flow of the sample fluid along a path through an element of porous media, or through multiple elements of porous media.

Abstract: Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described.

Abstract: A device for measuring blood coagulation time is formed from a first substrate; a second substrate; a spacer layer disposed between the first and second substrates, said spacer layer having an opening formed therein defining a sample receiving chamber, a vented sink chamber, and an elongated reservoir forming a conduit for liquid movement between the sample receiving chamber and the sink chamber; a first electrode disposed on the first substrate, said first electrode being exposed in the reservoir portion through a first opening in the spacer layer; and a second electrode disposed on the second substrate, said second electrode being exposed in the reservoir portion through a second opening in the spacer layer. The device of the invention is used in combination with an apparatus that is connected to the first and second electrodes for measuring current flow between the first and second electrodes.

Abstract: Embodiments of the present invention relate to multiple coagulation test cartridges and methods of using such cartridges. In one embodiment the cartridge is a disposable single-use cartridge for use in evaluating blood clotting. The cartridge includes multiple containers, such as tubes, each of which includes one or more coagulation affecting substances. The containers can be pre-filled with substances in amounts suitable for use with a single patient's blood sample. The cartridge may include one or more containers, each of which has multiple sections, or volumes, each section storing a different coagulation affecting substance. In another embodiment the cartridge is used in a method for determining at least one appropriate coagulation affecting substance for modifying a patient's coagulation status using a multiple coagulation test system.

Abstract: An assembly for testing platelet aggregation including an electrode subassembly that is mounted in a cuvette subassembly for use with relatively small samples containing platelets.

Abstract: Provided herein are various methods for determining heparin concentration or heparin response imbalance in native whole blood, citrated whole blood, or plasma by measuring two parameters that characterize each phase of a two-phase coagulation response, such as a time period until clot formation initiation and a post-initiation clot formation.

Abstract: The present invention is directed to a cartridge device for a measuring system for measuring viscoelastic characteristics of a sample liquid, in particular a blood sample, comprising a cartridge body having at least one measurement cavity formed therein and having at least one probe element arranged in said at least one measurement cavity for performing a test on said sample liquid; and a cover being attachable on said cartridge body; wherein said cover covers at least partially said at least one measurement cavity and forms a retaining element for retaining said probe element in a predetermined position within said at least one measurement cavity. The invention is directed to a measurement system and a method for measuring viscoelastic characteristics of a sample liquid.

Abstract: The present invention is directed to a cartridge device for a measuring system for measuring viscoelastic characteristics of a sample liquid, in particular a blood sample, comprising a cartridge body having at least one measurement cavity formed therein and having at least one probe element arranged in said at least one measurement cavity for performing a test on said sample liquid; and a cover being attachable on said cartridge body; wherein said cover covers at least partially said at least one measurement cavity and forms a retaining element for retaining said probe element in a predetermined position within said at least one measurement cavity. The invention is directed to a measurement system and a method for measuring viscoelastic characteristics of a sample liquid.

Abstract: The present invention is directed to a cartridge device for a measuring system for measuring viscoelastic characteristics of a sample liquid, in particular a blood sample, comprising a cartridge body having at least one measurement cavity formed therein and having at least one probe element arranged in said at least one measurement cavity for performing a test on said sample liquid; and a cover being attachable on said cartridge body; wherein said cover covers at least partially said at least one measurement cavity and forms a retaining element for retaining said probe element in a predetermined position within said at least one measurement cavity. The invention is directed to a measurement system and a method for measuring viscoelastic characteristics of a sample liquid.

Abstract: A cartridge device having a receiving portion for receiving a blood sample and a jack portion for receiving a plug; a stirring device for circulating the blood sample within the receiving portion; and an electrode holder having at least one incorporated electrode wire pair; wherein the electrode holder is attachable to the cell such that one end of the at least one electrode wire pair forms a sensor unit for measuring the electrical impedance between the two electrode wires of the at least one electrode wire pair within the blood sample and that the opposite end of the at least one electrode wire pair forms a plug portion being connectable directly to the plug for an electrical connection of the sensor unit to an analyzer.

Abstract: The present invention provides a blood coagulation promoter capable of exerting both excellent blood coagulation promoting ability and excellent blood clot detaching ability; and a blood collection tube accommodating the blood coagulation promoter. The present invention provides a blood coagulation promoter which includes a hardly water soluble polyoxyalkylene derivative; a partially saponificated polyvinyl alcohol; at least one substance selected from the group consisting of adsorptive inorganic substances and hydrolases capable of hydrolyzing a bond between Arg and an arbitrary amino acid reside and/or a bond between Lys and an arbitrary amino acid residue in a peptide chain; a polyvinylpyrrolidone; and preferably a water-soluble silicone oil, and a blood collection tube in which the blood coagulation promoter is accommodated in a tubular vessel having a bottom.

Abstract: Methods, systems, and computer readable media for using actuated surface-attached posts for assessing biofluid rheology are disclosed. According to one aspect, a method for testing properties of a biofluid specimen includes placing the specimen onto a micropost array having a plurality of microposts extending outwards from a substrate, wherein each micropost includes a proximal end attached to the substrate and a distal end opposite the proximal end, and generating an actuation force in proximity to the micropost array to actuate the microposts, thereby compelling at least some of the microposts to exhibit motion. The method further includes measuring the motion of at least one of the microposts in response to the actuation force and determining a property of the specimen based on the measured motion of the at least one micropost.

Abstract: The present invention provides novel compositions of binding moiety-nanoparticle conjugates, aggregates of these conjugates, and novel methods of using these conjugates, and aggregates. The nanoparticles in these conjugates can be magnetic metal oxides, either monodisperse or polydisperse. Binding moieties can be, e.g., oligonucleotides, polypeptides, or polysaccharides. Oligonucleotide sequences are linked to either non-polymer surface functionalized metal oxides or with functionalized polymers associated with the metal oxides. The novel compositions can be used in assays for detecting target molecules, such as nucleic acids and proteins, in vitro or as magnetic resonance (MR) contrast agents to detect target molecules in living organisms.

Abstract: The present invention provides methods for preventing or treating a condition characterized by undesired thrombosis in a mammal using a crystalline polymorph form of a maleate salt of a compound of Formula I that has activity against mammalian factor Xa.

Abstract: The present invention provides a reagent kit for detecting lupus anticoagulant which includes a first clotting time-measuring reagent containing manganese salt and a second clotting time-measuring reagent which contains manganese salt at a concentration lower than that of the first clotting time-measuring reagent or does not contain manganese salt and a method of determining the presence or absence of lupus anticoagulant using the kit.

Abstract: An analysis result providing system comprising, a sample analyzing section which analyzes a sample collected from a subject, a validation section which validates an analysis result obtained by the sample analyzing section, an e-mail sending section which sends, when an analysis result of the sample collected from the subject has been validated by the validation section, an e-mail for providing the analysis result; and a handheld device which is carried by the subject and which is capable of receiving the e-mail sent by the e-mail sending section and displaying a content of the e-mail.

Abstract: An embodiment relates to a method of detecting a drug resistance in a patient comprising adding nanoparticles to sample platelets to form activated platelets containing the nanoparticles and comparing a difference in activation of the activated platelets and the sample platelets. Another embodiment relates to a method of monitoring a thrombotic risk factor in a subject in a general population comprising adding nanoparticles to sample platelets to form activated platelets containing the nanoparticles and comparing a difference in activation of the activated platelets and the sample platelets. Yet another embodiment relates to a kit comprising nanoparticles, a fluorescence dye tagged antibody and optionally a buffer, wherein the kit is configured to detect a drug resistance in a patient or a likelihood of the thrombotic risk factor in a subject in general population.

Abstract: The present invention is in the field of coagulation diagnostics and relates to a screening process for finding samples containing antiphospholipid antibodies (lupus anticoagulants), wherein the platelet aggregation-stimulating action of said antiphospholipid antibodies is determined in vitro.

Abstract: When assessing the start time of the limulus reaction between biogenous biologically active substances and LAL and using the reaction start time to determine the concentration of the biogenous biologically active substances, in order to exclude the influence of progressive changes which occur regardless of the conditions of the limulus reaction, the strength of transmitted light or scattered light in the liquid mixture of the measurement sample and LAL is detected, the variation (delta) in the transmittance or number of gel particles is acquired at set intervals, and the time when the variation (delta) crosses a threshold value is taken as the reaction start time. Furthermore, the time intervals when acquiring the abovementioned delta are not uniform, and either change over time from the start of measurement as defined by a time function, or multiple sequences with differing time intervals are prepared in advance.

Abstract: The present invention provides pharmaceutical formulations including a non-anticoagulant, non-saccharide polymer that with at least one sulfate or sulfonate moiety. The pharmaceutical formulations of the invention are of use to improve blood clotting in a subject. Also provided are useful analytical methods utilizing these polymers to query the dynamics of blood clotting in vitro.

Abstract: High range activated clotting time (HR-ACT) tests detect blood clotting time in blood samples which have high levels of heparin. Reagents such as calcium chloride and kaolin within the test apparatus trigger clotting. Physical separation of the reagents from each other prevents interaction between them before the test sample introduction. In one embodiment, to improve dry kaolin re-suspension, kaolin may be suspended in water rather than buffered saline before being dispensed into the test chamber. The combination of removing the buffered saline and the calcium chloride from the kaolin suspension enables clot detection in blood samples containing 5-6 u/ml of heparin.

Abstract: An indicator device adapted give a detectable signal when the antioxidant capacity of a sample of a mammalian wound fluid exceeds a predetermined minimum level which is characteristic of an infected wound. Also provided system for use in the diagnosis and treatment of wounds comprising the inventive diagnostic device and a wound dressing comprising at least one antimicrobial agent for selective application to infected wounds. Also provided are methods of diagnosis and treatment by means of the inventive device and system.

Abstract: A device is provided for analyzing the coagulation and/or behavior of blood. The blood flows through an opening (9) that is disposed in a porous part (5) while a substance which influences blood aggregation can be delivered to the blood. A preliminary diffuser chamber (3) from which blood flows to the opening (9) is mounted upstream of the opening (9), and/or a secondary diffuser chamber (4) into which blood flows from the opening (9) is mounted downstream of the opening (9). The substance is arranged on the wall of the preliminary diffuser chamber (3) and/or the secondary diffuser chamber (4) in the form of a coating (8).

Abstract: A blood coagulation detection device includes a micro channel unit, an optical signal unit, an opto-electronic conversion circuit, an amplifier circuit, and a filter circuit. The micro channel unit has a sample detection area. The optical signal unit transmits a reference light to the micro channel unit so as to form a message light. The opto-electronic conversion circuit receives the message light and converts the message light into an electrical signal. The amplifier circuit is electrically connected to the opto-electronic conversion circuit for amplifying the electrical signal. The filter circuit is electrically connected to the amplifier circuit for filtering the amplified electrical signal.

Abstract: A method of monitoring thrombus formation is described, which comprises flowing anticoagulated blood into a thrombus formation chamber, in at least a part of which a thrombus formation inducer inducing thrombus formation is provided, while releasing the anticoagulant treatment or promoting blood coagulation to thereby monitor thrombus formation in the thrombus formation chamber.

Abstract: Methods and devices for conducting platelet aggregation analysis. A method for conducting platelet aggregation analysis by a cartridge device, including providing a blood sample in the cartridge device, stirring the blood sample within the cartridge device, measuring the electrical impedance between electrodes to obtain measured electrical impedance values, comparing measured electrical impedance values, discarding and repeating the measurements of the electrical impedance in case a variation of the measurements is outside a predetermined threshold range, or reporting the measured electrical impedance values in case the variation of the measurements is within the predetermined threshold range. Reported measured electrical impedance values indicate platelet aggregation in a blood sample.

Abstract: A test strip with a sample chamber is secured to a meter. The sample chamber in the portion of the test strip that extends out of the meter is illuminated by transmitting light from a light source inside the meter internally through the test strip towards the sample chamber. By way of analogy, the test strip acts in a fashion similar to a fiber optic cable or optical wave guide by transmitting the light from the meter to the remotely located sample chamber that extends outside the meter. The user is then able to easily see the sample chamber of the test strip in dark conditions so that the user is able to readily align the sample chamber with the drop of fluid on the skin as well as view the sample chamber in order to ensure proper filling. The light also illuminates a test strip slot into which the test strip is inserted.

Abstract: A sample analyzer is provided. The sample analyzer includes a reagent container holder, a measurement unit, and an information processing unit configured to perform operations including controlling the measurement unit to start the successive measurement of the plurality of samples, determining whether to switch from the first reagent container to the second reagent container while performing the successive measurement by using the reagent contained in the first reagent container, controlling the measurement unit to suspend a start of aspiration of a next sample, to measure a quality control measurement sample prepared from the reagent contained in the second reagent container, when determined to switch from the first reagent container to the second reagent container, and controlling the measurement unit to start the aspiration of the next sample when an analysis result of the quality control measurement sample meets a predetermined condition.

Abstract: A blood analyzing device (100) comprises a holder (110) for receiving a cuvette (20) with a blood sample (30). The device (100) induces a movement of the blood cells in the sample (30) by applying a field (230) over the cuvette (20). A detector (130) detects, based on output light from the blood sample (30) originating from a light source (120), a change in the induced movement of the cells caused by an increase in viscosity of the blood due to an aggregation and/or coagulation process. A processor (140) processes the detector reading and generates a signal representative of the hemostasis function of the tested blood.